It’s not hard to imagine AbbVie’s management team presented with PowerPoint decks showing ... the revenues lost as Humira succumbed to biosimilar competition, and leave the company with ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches ...

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

HYDERABAD, Jan 31 (Reuters) - Indian biopharmaceutical firm Biocon (BION.NS), opens new tab is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh) as a biosimilar of the original reference biologic tocilizumab (Actemra), according to a January 30 announcement ...

With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at ...

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar. January started ...